Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Nov 14, 2022

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

Oct 12, 2022

ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement

Sep 13, 2022

ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

Aug 15, 2022

ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

Aug 2, 2022

ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

Jul 27, 2022

ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

Jul 8, 2022

ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

Jun 27, 2022

PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

Jun 22, 2022

ProMIS Neurosciences Announces Debt Amendment and Conversion

Jun 22, 2022

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

  • arrow_back
  • 1…
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy